Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns

Core Viewpoint - Vaccine manufacturers are concerned about the U.S. advisory panel's decision to eliminate the longstanding recommendation for all infants to receive a hepatitis B vaccine at birth, indicating potential implications for public health and vaccination rates [1] Group 1: Industry Impact - The decision may lead to a decrease in hepatitis B vaccination rates among infants, which could affect overall public health outcomes [1] - Vaccine makers fear that this change could undermine efforts to control hepatitis B, a virus that can lead to serious health issues [1] Group 2: Company Reactions - Companies involved in vaccine production have expressed their worries regarding the potential decline in demand for the hepatitis B vaccine following the advisory panel's recommendation [1] - The shift in policy may prompt vaccine manufacturers to reassess their production and marketing strategies to adapt to the new guidelines [1]